JP2020507577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507577A5 JP2020507577A5 JP2019543270A JP2019543270A JP2020507577A5 JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5 JP 2019543270 A JP2019543270 A JP 2019543270A JP 2019543270 A JP2019543270 A JP 2019543270A JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022074378A JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457785P | 2017-02-10 | 2017-02-10 | |
| US62/457,785 | 2017-02-10 | ||
| PCT/US2018/017718 WO2018148610A1 (en) | 2017-02-10 | 2018-02-10 | Proteins binding psma, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074378A Division JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507577A JP2020507577A (ja) | 2020-03-12 |
| JP2020507577A5 true JP2020507577A5 (OSRAM) | 2021-03-25 |
Family
ID=63107819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543270A Withdrawn JP2020507577A (ja) | 2017-02-10 | 2018-02-10 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
| JP2022074378A Withdrawn JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074378A Withdrawn JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200024353A1 (OSRAM) |
| EP (1) | EP3579878A4 (OSRAM) |
| JP (2) | JP2020507577A (OSRAM) |
| KR (1) | KR20190120770A (OSRAM) |
| CN (1) | CN110913902A (OSRAM) |
| AU (1) | AU2018217834A1 (OSRAM) |
| BR (1) | BR112019016553A2 (OSRAM) |
| CA (1) | CA3053275A1 (OSRAM) |
| IL (1) | IL268574A (OSRAM) |
| MX (1) | MX2019009541A (OSRAM) |
| RU (1) | RU2019128204A (OSRAM) |
| SG (1) | SG11201907271PA (OSRAM) |
| WO (1) | WO2018148610A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN117881702A (zh) * | 2021-08-03 | 2024-04-12 | 山东先声生物制药有限公司 | 一种cd16抗体及其应用 |
| CN117915950A (zh) * | 2021-08-06 | 2024-04-19 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151873A0 (en) * | 2000-03-24 | 2003-04-10 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US6455712B1 (en) * | 2000-12-13 | 2002-09-24 | Shell Oil Company | Preparation of oxirane compounds |
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| US20090226466A1 (en) * | 2005-11-03 | 2009-09-10 | Sherman Fong | Therapeutic anti-her2 antibody fusion polypeptides |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| CA3102679A1 (en) * | 2007-12-14 | 2009-06-25 | Birgitte Urso | Antibodies against human nkg2d and uses thereof |
| WO2010118522A1 (en) * | 2009-04-14 | 2010-10-21 | Proscan Rx Pharma Inc. | Antibodies against prostate specific membrane antigen |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| RU2603093C2 (ru) * | 2010-04-15 | 2016-11-20 | Дженентек, Инк. | Антитела против полиубиквитина и способы их применения |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN107936121B (zh) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| KR20140054177A (ko) * | 2011-08-05 | 2014-05-08 | 제넨테크, 인크. | 항-폴리유비퀴틴 항체 및 이용 방법 |
| WO2014179363A1 (en) * | 2013-04-29 | 2014-11-06 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| TN2016000525A1 (en) * | 2014-05-29 | 2018-04-04 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| CA2964968A1 (en) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| SG11201705632UA (en) * | 2015-01-08 | 2017-08-30 | Kyowa Hakko Kirin Co Ltd | Bispecific antibody binding to trailr2 and psma |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| US10973914B2 (en) * | 2015-02-20 | 2021-04-13 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| WO2016135041A1 (en) * | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR102788389B1 (ko) * | 2015-04-06 | 2025-03-31 | 서브도메인, 엘엘씨 | 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도 |
| WO2016207273A2 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
-
2018
- 2018-02-10 AU AU2018217834A patent/AU2018217834A1/en not_active Abandoned
- 2018-02-10 MX MX2019009541A patent/MX2019009541A/es unknown
- 2018-02-10 KR KR1020197026585A patent/KR20190120770A/ko not_active Withdrawn
- 2018-02-10 EP EP18751484.9A patent/EP3579878A4/en not_active Withdrawn
- 2018-02-10 US US16/483,788 patent/US20200024353A1/en not_active Abandoned
- 2018-02-10 BR BR112019016553-3A patent/BR112019016553A2/pt not_active Application Discontinuation
- 2018-02-10 WO PCT/US2018/017718 patent/WO2018148610A1/en not_active Ceased
- 2018-02-10 CA CA3053275A patent/CA3053275A1/en active Pending
- 2018-02-10 CN CN201880024146.6A patent/CN110913902A/zh active Pending
- 2018-02-10 JP JP2019543270A patent/JP2020507577A/ja not_active Withdrawn
- 2018-02-10 SG SG11201907271PA patent/SG11201907271PA/en unknown
- 2018-02-10 RU RU2019128204A patent/RU2019128204A/ru unknown
-
2019
- 2019-08-07 IL IL268574A patent/IL268574A/en unknown
-
2022
- 2022-04-28 JP JP2022074378A patent/JP2022105121A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507577A5 (OSRAM) | ||
| JP2020510646A5 (OSRAM) | ||
| JP2020508997A5 (OSRAM) | ||
| JP2020507328A5 (OSRAM) | ||
| JP2023052214A5 (OSRAM) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098733A5 (OSRAM) | ||
| JP2023106433A5 (OSRAM) | ||
| JP2020521448A5 (OSRAM) | ||
| JP2021098732A5 (OSRAM) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2020522474A5 (OSRAM) | ||
| JP2020522473A5 (OSRAM) | ||
| JP2020529410A5 (OSRAM) | ||
| US11913025B2 (en) | Antigen-specific T cells and uses thereof | |
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2017535257A5 (OSRAM) | ||
| JP2020536532A5 (OSRAM) | ||
| JP2020531525A5 (OSRAM) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020514277A5 (OSRAM) | ||
| JP2018510617A5 (OSRAM) |